Strong efficacy and cardiovascular benefits should allow Novo to continue growing sales of GLP-1 therapies in diabetes. Ozempic and Rybelsus helped Novo gain share over Eli Lilly's once-weekly ...

India's anti-obesity drug market is valued at Rs 3,000-3,500 crore and is projected to grow nearly eightfold to Rs 25,000 ...

GoodRx reports that insurance coverage for GLP-1 medications varies. It's more likely when prescribed for FDA-approved uses ...

Weight-loss jabs could help minimise asthma symptoms in obese people, according to a study. The drugs should be explored as a ...

Researchers says the drugs could be a treatment for obese people with asthma who are ‘often resistant’ to steroids ...

A new study reports that mice shed about 20% of their body weight and saw their breast cancer tumors decrease after getting ...

Tirzepatide yielded greater cardiometabolic benefits, especially in total cholesterol, LDL cholesterol, and weight loss, among women than men.

GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.

Tirzepatide may confer larger increases in testosterone levels among men with metabolic hypogonadism than testosterone ...

Obesity has become a global epidemic, contributing to a host of chronic health conditions such as type 2 diabetes, ...

New study reveals weight-loss drugs help during treatment but weight returns rapidly after stopping. Here's what they found.